Similarly, AhR mediates the activation of PI3K/Akt and MEK/ERK signaling via Src kinase and induces resistance of EGFR-mutant NSCLC cells to an EGFR-TKi (Gefitinib) [116]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.